Aptar Pharma acquires Pulmotree to expand inhaler portfolio

Crystal Lake, Illinois - Aptar Pharma has announced the acquisition of PULMOTREE, a Munich-based life science company focused on pulmonary drug delivery systems. The deal will augment Aptar Pharma's respiratory drug delivery portfolio with PULMOTREE's Kolibri Non-Propellant Liquid Inhaler platform. This technology employs a breath-triggered vibrating mesh aerosolization engine, which is ideal for precise lung delivery and includes connectivity features for treatment monitoring.

Gael Touya, President and CEO of Aptar, highlighted the significance of this acquisition in reinforcing Aptar's position in respiratory drug delivery and broadening their capabilities for pharmaceutical partners. The Kolibri platform, designed to effectively deliver complex molecules including biologics, was developed over a two-year collaboration between the two companies.

Jonathan Mulpas, Director of Business Development in Pulmonary Category at Aptar, emphasized the organisations' joint efforts to allow pharmaceutical partners to assess the Kolibri platform. Ulf Krüger, CEO of PULMOTREE, confirmed that joining Aptar is the next logical step in their ongoing partnership. This acquisition is part of an exclusive collaboration agreement signed between Aptar Pharma and PULMOTREE in 2024.

Aptar Pharma, a part of the AptarGroup, Inc., employs 14,000 people across 20 countries. The financial details of the acquisition were not disclosed in the press release. This story, AI-supported, was reviewed by an editor.